M. Pierre-Yves Desbiens
Director/Board Member chez APTILON CORPORATION
Profil
M.
Pierre-Yves Desbiens is currently the Director at Replicor, Inc. He is also an Independent Director at DMDConnects Services, Inc. and the Chief Operating & Financial Officer at VuWall Technology, Inc. In the past, he served as an Independent Director at Æterna Zentaris, Inc., Director at Telesta Therapeutics, Inc., Genizon Biosciences, Inc., and the University of Quebec.
He was also the Principal at Domtar, Inc. and PricewaterhouseCoopers LLP.
Additionally, he served as the Chief Financial Officer & General Manager at Horizon Sciences & Technologies, Inc. and the Chief Financial Officer & VP-Administration at Supratek Pharma, Inc. He was the Vice President-Finance & Administration at Chronogen, Inc. and Vice President-Finance at PurGenesis Technologies, Inc. He also served as the Chief Operating Officer at Neomed Institute.
Mr. Desbiens holds an MBA degree from the University of Montréal and an undergraduate degree from the University of Quebec.
Postes actifs de M. Pierre-Yves Desbiens
| Sociétés | Poste | Début |
|---|---|---|
| APTILON CORPORATION | Director/Board Member | 16/05/2018 |
Anciens postes connus de M. Pierre-Yves Desbiens
| Sociétés | Poste | Fin |
|---|---|---|
| AETERNA ZENTARIS INC. | Director/Board Member | 05/05/2021 |
Genizon Biosciences, Inc.
 Genizon Biosciences, Inc. BiotechnologyHealth Technology Genizon Biosciences Inc. discovers genes and biomarkers in common diseases using genome wide association studies (GWAS), leveraging its proven and proprietary technology platform and access to patients from the Quebec Founder Population. Genizon has one of the largest GWAS programs worldwide, addressing many common diseases and traits. Several of these have been successfully completed, generating comprehensive maps of interacting genes, biomarkers and biological disease pathways (known as GeneMaps), providing strong validation of the power of the Company's discovery platform. Genizon has out-licensed some of the therapeutic and diagnostic rights to GeneMaps for Crohn's disease (to Genentech) and attention deficit hyperactivity disorder, endometriosis and Alzheimer's disease (disease-state diagnostic rights to Pfizer). GeneMaps have also been generated from GWAS in schizophrenia, psoriasis and longevity. GWAS are in progress for rheumatoid arthritis, Alzheimer's disease, and coronary heart disease and its precursors, obesity, type II diabetes, dyslipidemia and hypertension (collectively metabolic syndrome). Genizon's technology platform and discoveries can complement current R&D programs by using human genetics to significantly enhance research and by adding value at multiple stages of the drug development process. Genizon is continually developing and enhancing its gene and biomarker discovery platform. For example, the company is assessing the role of copy number variations (CNVs) in diseases- applying new methods to ongoing large-scale GWAS in rheumatoid arthritis and metabolic syndrome, and retrospectively to previous studies. Genizon also leverages its platform and expertise by offering high throughput, high quality SNP genotyping, statistical genetics, gene expression and pharmacogenomics services to academic institutions, research organizations and the biopharmaceutical industry. | Director/Board Member | 30/05/2012 |
Neomed Institute
 Neomed Institute Pharmaceuticals: OtherHealth Technology Neomed Institute operated as a non-profit organization for pharmaceutical companies. It offered analytical services, drug development, licensing, and drug discovery. The company was founded in 2012 and was headquartered in Montreal, Canada. | Chief Operating Officer | - |
Horizon Sciences & Technologies, Inc.
 Horizon Sciences & Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Teva Pharmaceutical Industries Ltd., Horizon Sciences & Technologies, Inc. is a Canadian company that researches and develops pharmaceutical technology. The private company is based in Montréal, Canada. | Director of Finance/CFO | - |
Formation de M. Pierre-Yves Desbiens
| University of Montréal | Masters Business Admin |
| University of Quebec | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| AETERNA ZENTARIS INC. | Health Technology |
| Entreprise privées | 9 |
|---|---|
Domtar, Inc.
 Domtar, Inc. Pulp & PaperProcess Industries Domtar, Inc. manufactures paper, pulp and forest products. The company manufactures business papers, commercial printing, publication and technical specialty papers. The company is headquartered in Montréal, Canada. | Process Industries |
Telesta Therapeutics, Inc.
 Telesta Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Telesta Therapeutics, Inc. is a biotechnology company, which focuses on the licensing/acquisition and development of transformational therapeutics for the treatment of serious human diseases, such as cancer, immune diseases, and targeted rare diseases. The company was founded by Graeme McRae in 1979 and is headquartered in Pointe-Claire, Canada. | Health Technology |
Horizon Sciences & Technologies, Inc.
Horizon Sciences & Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Teva Pharmaceutical Industries Ltd., Horizon Sciences & Technologies, Inc. is a Canadian company that researches and develops pharmaceutical technology. The private company is based in Montréal, Canada. | Commercial Services |
PricewaterhouseCoopers LLP
 PricewaterhouseCoopers LLP Miscellaneous Commercial ServicesCommercial Services PricewaterhouseCoopers LLC provides assurance, tax and advisory services. Its services include audit and assurance, consulting, deals, human resources, legal, tax, and family business. The firm also offers accountability, risk management, structuring, mergers and acquisitions, and performance and process improvement. The company was founded in 1998 and is headquartered in Buffalo, NY. | Commercial Services |
PurGenesis Technologies, Inc.
 PurGenesis Technologies, Inc. Pharmaceuticals: MajorHealth Technology PurGenesis Technologies, Inc. develops and manufactures patented ingredients from natural sources. It offers anti-aging and sun care products for the cosmeceutical market. The firm develops prescription botanically-sourced therapeutics that address areas of unmet medical need. The company was founded by Purcell Marc in 1999 and is headquartered in Montmagny, Canada. | Health Technology |
Supratek Pharma, Inc.
 Supratek Pharma, Inc. Pharmaceuticals: MajorHealth Technology Supratek Pharma, Inc. develops drugs and related oncology therapeutic products. It offers injectable chemotherapeutic that enhances or enables an approved anticancer drug. The firm’s products include SP1014C - a novel cabazitaxel against drug resistant prostate cancer, SP1030C - novel bendamustine against chronic lymphocytic leukemia and non-Hodgkin’s lymphoma and SP1049C - a novel injectable anthracycline platform drug against chemoresistant cancers. The company was founded by Valery Alakhov in 1994 and is headquartered in Pointe-Claire, Canada. | Health Technology |
Genizon Biosciences, Inc.
Genizon Biosciences, Inc. BiotechnologyHealth Technology Genizon Biosciences Inc. discovers genes and biomarkers in common diseases using genome wide association studies (GWAS), leveraging its proven and proprietary technology platform and access to patients from the Quebec Founder Population. Genizon has one of the largest GWAS programs worldwide, addressing many common diseases and traits. Several of these have been successfully completed, generating comprehensive maps of interacting genes, biomarkers and biological disease pathways (known as GeneMaps), providing strong validation of the power of the Company's discovery platform. Genizon has out-licensed some of the therapeutic and diagnostic rights to GeneMaps for Crohn's disease (to Genentech) and attention deficit hyperactivity disorder, endometriosis and Alzheimer's disease (disease-state diagnostic rights to Pfizer). GeneMaps have also been generated from GWAS in schizophrenia, psoriasis and longevity. GWAS are in progress for rheumatoid arthritis, Alzheimer's disease, and coronary heart disease and its precursors, obesity, type II diabetes, dyslipidemia and hypertension (collectively metabolic syndrome). Genizon's technology platform and discoveries can complement current R&D programs by using human genetics to significantly enhance research and by adding value at multiple stages of the drug development process. Genizon is continually developing and enhancing its gene and biomarker discovery platform. For example, the company is assessing the role of copy number variations (CNVs) in diseases- applying new methods to ongoing large-scale GWAS in rheumatoid arthritis and metabolic syndrome, and retrospectively to previous studies. Genizon also leverages its platform and expertise by offering high throughput, high quality SNP genotyping, statistical genetics, gene expression and pharmacogenomics services to academic institutions, research organizations and the biopharmaceutical industry. | Health Technology |
DMDConnects Services, Inc.
 DMDConnects Services, Inc. Advertising/Marketing ServicesCommercial Services DMDConnects Services, Inc. engages in enabling pharmaceutical, healthcare organizations, pharmaceutical marketing companies, and digital advertising agencies to reach, message, connect, and interact with physicians and healthcare professionals via multiple access channels. It also provides services such as targeted impressions and interactions through permission-based email, targeted on-line ad-serving, and mobile app advertising channels. The company was founded by Mark Benthin and Denis Martineau on April 1, 2005 and is headquartered in Longueuil, Canada. | Commercial Services |
Neomed Institute
Neomed Institute Pharmaceuticals: OtherHealth Technology Neomed Institute operated as a non-profit organization for pharmaceutical companies. It offered analytical services, drug development, licensing, and drug discovery. The company was founded in 2012 and was headquartered in Montreal, Canada. | Health Technology |
